Biotechnology Company



Funding Goal
Funding Raised So Far $49,200,000
Funding Commitments $0
Funding Remaining
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Company Overview

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value.

The company's lead product, the PLAC Test, measures Lp-PLA2 (lipoprotein-associated phospholipase A2) a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiovascular events. The PLAC Test is the only blood test cleared by the FDA as an aid in assessing risk for coronary heart disease, and ischemic stroke associated with atherosclerosis.

lock icon

Invest in Company

Sign up or log in now to unlock profile details and access financials, company documents, and invest in companies.

Business Summary

Company Age
Prior Year Revenue
Current Year Revenue
Next Year Revenue


PLAC Test for Lp-PLA2

The PLAC Test for Lp-PLA2

The PLAC Test for Lp-PLA2 is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis.

Early detection and more aggressive treatment can help prevent these cardiovascular events.

The PLAC Test measures Lp-PLA2 (lipoprotein-associated phospholipase A2), a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiac events.
50% of cardiovascular events strike in patients with unremarkable lipid levels, highlighting the prevalence of hidden cardiovascular risk.
A substantial body of evidence including over 50 studies and abstracts in peer-reviewed journals and conferences support Lp-PLA2 as a cardiovascular risk marker that provides new information, over and above traditional risk factors.


William Gerber
Chief Executive Officer
William G......

William G......, MD, is an Investment Partner at Bay City Capital and has been with the firm since September 1999.

He was most recently President and Chief Executive Officer of Epoch BioSciences, which was acquired by Nanogen in 2004.

Prior to joining Epoch, Dr. G...... served as President and Chief Executive Officer of diaDexus LLC, a joint venture established by Incyte Pharmaceuticals and SmithKline Beecham to apply genomics to the discovery of novel diagnostic products.

Dr. G...... previously served as Vice President and Chief Operating Officer of Onyx Pharmaceuticals, as President of Chiron Diagnostics, and as Senior Vice President and General Manager of the PCR Division of Cetus Corporation.

Dr. G...... is a member of the board of directors of Aviir, Inc., ITC, Nabsys and SynGen, Inc. He also served on and was President of the Board of Medical Quality Assurance, State of California.

Louis Bock
Louis B......

Lou focuses on identifying emerging biopharmaceutical, device and platform technology companies. He sits on the Boards of Ascenta Therapeutics, Century Hospice, Horizon Pharma, Orexigen Therapeutics, SGX Pharmaceuticals, Sonexa Therapeutics and Zogenix. He is responsible for ScaleVPs investments in Dynavax Technologies (NASDAQ: DVAX), Prestwick Pharmaceuticals, Seattle Genetics (NASDAQ: SGEN) and Somaxon (NASDAQ: SOMX).

Lou joined ScaleVP in 1997 from Gilead Sciences, where he held positions in research, project management, business development and sales. While at Gilead, Lou was the project manager for Gileads approved antiviral drug, Vistide, and was responsible for the discovery of Gileads novel thrombin aptamer. Prior to Gilead, he was a research associate at Genentech.

Vice President
R. M......

Mike has more than 30 years of experience in diagnostics and personalized medicine, with a focus on product development, market development, marketing, and sales management.

Most recently, Mr. was president of Tethys Bioscience, Inc., a commercial cardiometabolic diagnostics company with biomarker-based blood tests for cardiac event and diabetes prediction, where he led medical and regulatory affairs as well as business and corporate development.

Prior to that, as vice president of Marketing at Chiron Diagnostics his responsibilities included global sales, marketing, technical service, market development , and medical research. During his tenure at Chiron, pioneered a "therametrics" program that paired a proprietary diagnostic with a newly-approved therapeutic to identify and treat patients most at risk for HIV disease progression.

Mohan Iyer
Mohan I......

Mohan I...... brings 25 years of experience in the healthcare sector in a range of functions.

Most recently, he was Chief Financial and Business Officer of Tethys Bioscience, a venture backed company dedicated to the discovery, development and commercialization of biomarkers for chronic metabolic diseases.

Previously, he was Managing Director in the merchant banking group at Burrill & Company where he advised biotech companies on partnering and M&A transactions. He also spent seven years as a member of the executive team at diaDexus where he played a key role in the commercialization of a novel diagnostic product for cardiovascular risk assessment.

He holds a BS in Chemical Engineering from the University of Tennessee, an MS in Biomedical Engineering from Duke University and an MBA from Yale University.

Andrew G......

Andrew G...... is Vice President of Finance and Chief Financial Officer of Nevro Corp. Prior to joining Nevro, Andrew held the same position at OOMA, a consumer electronics manufacturer and VOIP service provider, and before that, Andrew was VP Finance and CFO of Reliant Technologies, a pioneer of fractional resurfacing skin treatments with aesthetic lasers. He has also held the top financial executive position with Metrika, Corcept Therapeutics, Amira Medical, Molecular Devices and several other medical device companies. Andrew began his career at KPMG and Raychem. He brings to Nevro many years of experience in financing the commercialization of innovative device and diagnostic technologies, both in the public and private arena. Andrew received his degree in Business Studies from Trinity College, Dublin, Ireland. He is a Fellow of the Institute of Chartered Accountants in Ireland.


Funding Goal
Funding Raised So Far $49,200,000
Funding Commitments $0
Funding Remaining
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding




South San Francisco, CA 94083, US

Top 10 Tips for Entrepreneurs Seeking Funding

Users who follow these tips increase their fundraising odds substantially.

  • Complete Your Funding Profile
    • Complete your funding profile with all sections filled, including your products and services, a complete management team with headshots, and slideshow with product images.
  • Complete a Business Plan (Optional)
    • Complete a Business Plan in EquityNet and refine your financial projections using the benchmarking alerts in the Business Plan Analysis report.
  • Upload Important Investment Documents
    • Upload and present any other important investment documents such as pitch decks, financial statements, and offering materials.
  • Use EquityNet Crowdcast
    • Use the EquityNet Crowdcast system to automatically email invitations to your contacts in order to build additional exposure for your company.
  • Construct Concise Introductory Messages
    • Construct and send a concise introductory message to investors, including primary reasons why they should want to invest such as KPIs, expected returns, and forecasted revenue.
  • Be Proactive in Messaging Investors
    • Be proactive in messaging many investors and include a simple way for them to connect with you for a web meeting or call, such as a Calendly link.
  • Use the Activity System
    • Use the Activity system to track interested investors, and send prompt follow-up messages to investors who viewed your profile or showed interest.
  • Prepare for Due Diligence
    • Prepare for due diligence questions by interested investors and use your Business Plan and investment documents to satisfy such requests.
  • Keep Your Funding Profile Updated
    • Keep your funding profile updated with new funding raised/committed and message interested investors with any new milestones achieved.
  • Do Not Respond to Unknown Investors
    • Do not respond to or engage any parties outside of EquityNet that are not listed as approved investors (this may happen due to your public profile and LinkedIn connections).